Health Technology · Pharmaceuticals: Major · NSE: MOREPENLAB · data 2026-10-09
Morepen Laboratories Limited
Health check: Strong (6.7/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹129.55
Market cap
₹7,485 cr
P/E
50.5
P/B
—
ROE
7.9%
ROCE
6.2%
Debt / equity
0.17
Dividend yield
0.15%
1-year return
169.1%
52-week high
₹150.7
52-week low
₹33.05
Operating margin
7.6%
Growth
| Revenue (last 12 months) | ₹1,951 cr |
| Net profit (last 12 months) | ₹141 cr |
| Sales growth, 3 years (yearly) | 8.4% |
| Profit growth, 3 years (yearly) | 34.9% |
Shareholding (2026-09-30)
| Promoters | 35.65% |
| Foreign institutions (FII) | 3.43% |
| Domestic institutions (DII) | 1.71% |
| Public | 64.35% |
| Promoter shares pledged | 0.00% |
| Number of shareholders | 4,03,932 |
Similar companies
Suven Life Sciences Limited (SUVEN) · Aarti Pharmalabs Limited (AARTIPHARM) · Bliss GVS Pharma Limited (BLISSGVS) · Symbiotec Pharmalab Limited (SYMBIOTEC) · Supriya Lifescience Limited (SUPRIYA)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open MOREPENLAB in NSE Scanner →